MilliporeSigma
Search Within

AB1056

Applied Filters:
Keyword:'AB1056'
Showing 1-30 of 30 results for "AB1056" within Papers
Robert Root-Bernstein et al.
International journal of molecular sciences, 23(19) (2022-10-15)
COVID-19 patients often develop coagulopathies including microclotting, thrombotic strokes or thrombocytopenia. Autoantibodies are present against blood-related proteins including cardiolipin (CL), serum albumin (SA), platelet factor 4 (PF4), beta 2 glycoprotein 1 (β2GPI), phosphodiesterases (PDE), and coagulation factors such as Factor
Oncolytic adenovirus expressing a p53 variant resistant to degradation by HPV E6 protein exhibits potent and selective replication in cervical cancer.
Heideman, DA; Steenbergen, RD; van der Torre, J; Scheffner, M; Alemany, R; Gerritsen et al.
Molecular Therapy null
Clostridia and Enteroviruses as Synergistic Triggers of Type 1 Diabetes Mellitus.
Root-Bernstein, et al.
International Journal of Molecular Sciences, 24 (2023)
Donna L Mallery et al.
Proceedings of the National Academy of Sciences of the United States of America, 107(46), 19985-19990 (2010-11-04)
Antibodies provide effective antiviral immunity despite the fact that viruses escape into cells when they infect. Here we show that antibodies remain attached to viruses after cell infection and mediate an intracellular immune response that disables virions in the cytosol.
Eduardo G Cafferata et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 15(9), 3037-3049 (2009-04-02)
A33 antigen is a membrane-bound protein expressed in intestinal epithelium that is overexpressed in 95% of primary and metastatic colorectal carcinomas but is absent in most epithelial tissues and tumor types. We hypothesized that A33 promoter might be useful in
Construction of an infectious clone of human adenovirus type 41.
Duo-Ling Chen,Liu-Xin Dong,Meng Li,Xiao-Juan Guo,Min Wang,Xin-Feng Liu,Zhuo-Zhuang Lu,Tao Hung
Archives of Virology null
Wan-Chi Hsiao et al.
Molecular pharmaceutics, 9(5), 1396-1408 (2012-04-07)
Cell-based carriers were recently exploited as a tumor-targeting tool to improve systemic delivery of oncolytic viruses for cancer therapy. However, the slow clearance of carrier cells from normal organs indicates the need for a controllable system which allows viral delivery
Nuclear import of adenovirus DNA in vitro involves the nuclear protein import pathway and hsc70.
A C Saphire, T Guan, E C Schirmer, G R Nemerow, L Gerace
The Journal of Biological Chemistry null
J-W Choi et al.
Gene therapy, 20(9), 880-892 (2013-03-22)
Adenoviruses (Ad) have been investigated for their efficacy in reducing primary tumors after local intratumoral administration. Despite high Ad concentrations and repetitive administration, the therapeutic efficacy of Ad has been limited because of rapid dissemination of the Ad into the
Hongju Wu et al.
Journal of virology, 76(24), 12775-12782 (2002-11-20)
Adenovirus serotype 5 (Ad5) has great potential for gene therapy applications. A major limitation, however, is the host immune response against Ad5 infection that often prevents the readministration of Ad5 vectors. In this regard, the most abundant capsid protein, hexon
Oncolytic virus therapy for pancreatic cancer using the adenovirus library displaying random peptides on the fiber knob.
T Nishimoto,K Yoshida,Y Miura,A Kobayashi,H Hara,S Ohnami,K Kurisu,T Yoshida,K Aoki
Gene Therapy null
Marc Garcia-Moure et al.
Scientific reports, 9(1), 14368-14368 (2019-10-09)
Last advances in the treatment of pediatric tumors has led to an increase of survival rates of children affected by primitive neuroectodermal tumors, however, still a significant amount of the patients do not overcome the disease. In addition, the survivors
Oncolytic adenovirus targeting cyclin E overexpression repressed tumor growth in syngeneic immunocompetent mice.
Cheng, PH; Rao, XM; Wechman, SL; Li, XF; McMasters, KM; Zhou, HS
BMC Cancer null
Larisa I Labzin et al.
The EMBO journal, 38(21), e101365-e101365 (2019-08-31)
Inflammasomes are potent innate immune signalling complexes that couple cytokine release with pro-inflammatory cell death. However, pathogens have evolved strategies to evade this cell autonomous system. Here, we show how antibodies combine with innate sensors in primary human macrophages to
A-Rum Yoon et al.
Human gene therapy, 17(4), 379-390 (2006-04-14)
Oncolytic adenoviruses are currently being developed as novel antitumor therapeutics. To enhance their therapeutic potential, adenoviruses are being administered in combination with standard chemotherapy. Adenoviral vectors used in these clinical trials, however, can be destructive as they encode intact E1B
A hypoxia- and {alpha}-fetoprotein-dependent oncolytic adenovirus exhibits specific killing of hepatocellular carcinomas.
Kwon, OJ; Kim, PH; Huyn, S; Wu, L; Kim, M; Yun, CO
Clinical cancer research : an official journal of the American Association for Cancer Research null
Identification of sites in adenovirus hexon for foreign peptide incorporation.
Wu, H; Han, T; Belousova, N; Krasnykh, V; Kashentseva, E; Dmitriev, I; Kataram et al.
Journal of virology null
M Verónica Lopez et al.
PloS one, 4(4), e5119-e5119 (2009-04-02)
The clinical efficacy of conditionally replicative oncolytic adenoviruses (CRAd) is still limited by the inefficient infection of the tumor mass. Since tumor growth is essentially the result of a continuous cross-talk between malignant and tumor-associated stromal cells, targeting both cell
Highly efficient and carcinoma-specific adenoviral replication restricted by the EGP-2 promoter.
W M Gommans, P M J McLaughlin, J A C Schalk, G M M Groothuis, H J Haisma, M G Rots
Journal of Controlled Release : Official Journal of the Controlled Release Society null
Pei-Hsin Cheng et al.
Journal of molecular medicine (Berlin, Germany), 93(2), 211-223 (2014-11-08)
Oncolytic virotherapy can selectively destroy cancer cells and is a potential approach in cancer treatment. A strategy to increase tumor-specific selectivity is to control the expression of a key regulatory viral gene with a tumor-specific promoter. We have previously found
Lynette M Phillips et al.
Neuro-oncology, 23(11), 1911-1921 (2021-06-02)
Oncolytic adenoviruses are promising new treatments against solid tumors, particularly for glioblastoma (GBM), and preclinical models are required to evaluate the mechanisms of efficacy. However, due to the species selectivity of adenovirus, there is currently no single animal model that
Robert Root-Bernstein et al.
International journal of molecular sciences, 24(15) (2023-08-12)
Autoimmune cardiopathies (AC) following COVID-19 and vaccination against SARS-CoV-2 occur at significant rates but are of unknown etiology. This study investigated the possible roles of viral and bacterial mimicry, as well as viral-bacterial co-infections, as possible inducers of COVID-19 AC
Maria Bottermann et al.
Cell host & microbe, 25(4), 617-629 (2019-03-31)
The complement system is vital for anti-microbial defense. In the classical pathway, pathogen-bound antibody recruits the C1 complex (C1qC1r2C1s2) that initiates a cleavage cascade involving C2, C3, C4, and C5 and triggering microbial clearance. We demonstrate a C4-dependent antiviral mechanism
Matthew Glen Robertson et al.
Molecular therapy oncolytics, 20, 659-668 (2021-04-06)
Encoding the sodium iodide symporter (NIS) by an adenovirus (Ad) is a promising strategy to facilitate non-invasive imaging and radiotherapy of pancreatic cancer. However, insufficient levels of NIS expression in tumor cells have limited its clinical translation. To optimize Ad-based
Frederick F Lang et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 36(14), 1419-1427 (2018-02-13)
Purpose DNX-2401 (Delta-24-RGD; tasadenoturev) is a tumor-selective, replication-competent oncolytic adenovirus. Preclinical studies demonstrated antiglioma efficacy, but the effects and mechanisms of action have not been evaluated in patients. Methods A phase I, dose-escalation, biologic-end-point clinical trial of DNX-2401 was conducted
Conditionally replicative adenovirus with tropism expanded towards integrins inhibits osteosarcoma tumor growth in vitro and in vivo.
Adhiambo M Witlox, Victor W Van Beusechem, Bonnie Molenaar, Hans Bras, Gerard R Schaap et al.
Clinical cancer research : an official journal of the American Association for Cancer Research null
Naiara Martínez-Vélez et al.
Nature communications, 10(1), 2235-2235 (2019-05-30)
Pediatric high-grade glioma (pHGG) and diffuse intrinsic pontine gliomas (DIPGs) are aggressive pediatric brain tumors in desperate need of a curative treatment. Oncolytic virotherapy is emerging as a solid therapeutic approach. Delta-24-RGD is a replication competent adenovirus engineered to replicate
Isolated limb perfusion: a novel delivery system for wild-type p53 and fiber-modified oncolytic adenoviruses to extremity sarcoma.
Hannay, J; Davis, JJ; Yu, D; Liu, J; Fang, B; Pollock, RE; Lev, D
Gene Therapy null
Jana Koch et al.
Nature communications, 13(1), 4689-4689 (2022-08-11)
CDK4/6 inhibitors (CDK4/6i) and oncolytic viruses are promising therapeutic agents for the treatment of various cancers. As single agents, CDK4/6 inhibitors that are approved for the treatment of breast cancer in combination with endocrine therapy cause G1 cell cycle arrest
Felix Hauler et al.
Proceedings of the National Academy of Sciences of the United States of America, 109(48), 19733-19738 (2012-10-24)
Tripartite motif-containing 21 (TRIM21) is a cytosolic IgG receptor that mediates intracellular virus neutralization by antibody. TRIM21 targets virions for destruction in the proteasome, but it is unclear how a substrate as large as a viral capsid is degraded. Here
Page 1 of 1